Bibliografía
MELENA DE LEÓN
- Chong, P. S., Fung, M. L., Wong, K. H., & Lim, L. W. (2020). Therapeutic potential of Hericium erinaceus for depressive disorder. International journal of molecular sciences, 21(1), 163.
- Hu, J. H., Li, I. C., Lin, T. W., Chen, W. P., Lee, L. Y., Chen, C. C., & Kuo, C. F. (2019). Absolute Bioavailability, Tissue Distribution, and Excretion of Erinacine S in Hericium erinaceus Mycelia. Molecules (Basel, Switzerland), 24(8), 1624. https://doi.org/10.3390/molecules24081624
- Inanaga, K., Yoshida, M., Tomita, O., & Uchimura, N. (2015). Treatment of Mild Neurocognitive Disorder with Compounds from Hericium Erinaceum. International Medical Journal, 22(3).
- Kawagishi, H., Ando, M., Sakamoto, H., Yoshida, S., Ojima, F., Ishiguro, Y.,Furukawa, S. (1991). Hericenones C, D and E, stimulators of nerve growth factor (NGF)-synthesis, from the mushroom Hericium erinaceum. Tetrahedron Letters, 32(35), 4561–4564. doi:10.1016/0040-4039(91)80039-9
- Kawagishi, H., Zhuang, C., & Shnidman, E. (2004). The anti-dementia effect of Lion’s Mane mushroom (Hericium erinaceum) and its clinical application. Townsend letter for doctors and Patients, (249), 54-57.
- Kim, Y. O., Lee, S. W., & Kim, J. S. (2014). A comprehensive review of the therapeutic effects of Hericium erinaceus in neurodegenerative disease. Journal of Mushroom, 12(2), 77-81.
- Lai, P. L., Naidu, M., Sabaratnam, V., Wong, K. H., David, R. P., Kuppusamy, U. R., et al. (2013). Neurotrophic properties of the Lion’s mane medicinal mushroom, Hericium erinaceus (higher basidiomycetes) from Malaysia. Int. J. Med. Mushrooms 15, 539–554. doi: 10.1615/intjmedmushr.v15.i6.30
- Li, I. C., Lee, L. Y., Tzeng, T. T., Chen, W. P., Chen, Y. P., Shiao, Y. J., & Chen, C. C. (2018). Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines. Behavioural neurology, 2018, 5802634. https://doi.org/10.1155/2018/5802634
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009 Mar;23(3):367-72. doi: 10.1002/ptr.2634. PMID: 18844328.
- Mori, K., Inatomi, S., Ouchi, K., Azumi, Y., & Tuchida, T. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: A double‐blind placebo‐controlled clinical trial. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives, 23(3), 367-372.
- Mori, K., Obara, Y., Hirota, M., Azumi, Y., Kinugasa, S., Inatomi, S., & Nakahata, N. (2008). Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biological and Pharmaceutical Bulletin, 31(9), 1727-1732.
- Phan, C.-W., Lee, G.-S., Hong, S.-L., Wong, Y.-T., Brkljača, R., Urban, S., … Sabaratnam, V. (2014). Hericium erinaceus (Bull.: Fr) Pers. cultivated under tropical conditions: isolation of hericenones and demonstration of NGF-mediated neurite outgrowth in PC12 cells via MEK/ERK and PI3K-Akt signaling pathways. Food Funct., 5(12), 3160–3169. doi:10.1039/c4fo00452c
- Rupcic, Z., Rascher, M., Kanaki, S., Köster, R. W., Stadler, M., & Wittstein, K. (2018). Two new cyathane diterpenoids from mycelial cultures of the medicinal mushroom Hericium erinaceus and the rare species, Hericium flagellum. International journal of molecular sciences, 19(3), 740.
- Shimbo, M., Kawagishi, H., and Yokogoshi, H. (2005). Erinacine A increases catecholamine and nerve growth factor content in the central nervous system of rats. Nutr. Res. 25, 617–623.
- Vigna, L., Morelli, F., Agnelli, G. M., Napolitano, F., Ratto, D., Occhinegro, A., … & Rossi, P. (2019). Hericium erinaceus improves mood and sleep disorders in patients affected by overweight or obesity: could circulating pro-BDNF and BDNF be potential biomarkers?. Evidence-Based Complementary and Alternative Medicine, 2019.
